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Abstract The diuretic drug ethacrynic acid, an inhibitor of pi 
class glutathione S-transferase, has been tested in clinical trials 
as an adjuvant in chemotherapy. We recently solved the crystal 
structure of this enzyme in complex with ethacrynic acid and its 
glutathione conjugate. Here we present a new structure of the 
ethacrynic-glutathione conjugate complex. In this structure the 
ethacrynic moiety of the complex is shown to bind in a 
completely different orientation to that previously observed. 
Thus there are at least two binding modes possible, an 
observation of great importance to the design of second 
generation inhibitors of the enzyme. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The glutathione S-transferases (GSTs, EC 2.5.1.18) are a 
family of enzymes that conjugate electrophilic substrates to 
the tripeptide glutathione (GSH, γ-Glu-Cys-Gly). GSTs have 
been used as markers for malignant tumours and have been 
implicated in the development of resistance of tumours to-
wards various anti-cancer drugs [1^1]. The pi class isoform 
of GSTs, in particular, has been implicated in resistance and 
there are currently major efforts to find specific inhibitors of 
this isoform to be used as adjuvants in chemotherapy [4]. The 
diuretic drug ethacrynic acid (EA, [2,3-dichloro-4-(2-methyl-
enebutyryl)-phenoxy]acetic acid, see Fig. 1) is an inhibitor of 
pi class GSTs [5]. A number of investigators have explored the 
possibility of inhibiting GSTs with EA as a means of over-
coming acquired multi-drug resistance [6-8]. In a recent study, 
EA was administered in conjunction with thiotepa to 27 pre-
viously treated patients with advanced cancer [9]. Pi class GST 
activity was reduced and the tumours were found to have 
increased sensitivity to thiotepa. However, EA was found to 
cause side-effects that proved too severe to continue with 
phase II trials of the inhibitor. 
EA is a known inhibitor of GSTs but in addition can act as 
a substrate. EA is thought to form a conjugate with GSH via 
Michael addition, both spontaneously and by GST-driven 
catalysis [5,10,11]. The α,β-unsaturated ketone moiety (Fig. 
1) is the target for conjugation by GSH [11]. The reaction 
of the pi class GST with EA is often considered a character-
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istic feature of this isoenzyme [12]. The EA-GSH conjugate 
also acts as an inhibitor. In the case of human pi class GST 
the EA-GSH conjugate is a more potent inhibitor than the 
parent compound (A4 = 1.5 vs 11.5 μΜ, respectively) [11]. 
The first structures of a GST complexed with EA and its 
glutathione conjugate were determined by Cameron and co-
workers [13] who crystallised the complexes in the presence of 
the human alpha class enzyme. Although the alpha class en-
zyme possesses the canonical GST fold, it shares only 32% 
sequence identity with the pi class enzyme and has a C-termi-
nal extension that folds into part of the active site. We re-
cently solved the crystal structure of human pi class GST Pl-1 
in complex with the same inhibitors [14]. We have since dis-
covered that the glutathione conjugate of EA can bind in an 
alternative mode to the one that was recently described. Here 
we present the new structure and discuss it in the light of the 
previously published results. The difference in the two struc-
tures can be ascribed to different crystallisation conditions : in 
the published structure, the inhibitor was soaked into pre-
formed crystals whereas in the structure reported here, the 
complex was formed by cocrystallisation. The binding of 
EA-GSH in two different modes to the enzyme has implica-
tions for the design of second generation inhibitors of the 
enzyme. 
2. Material and methods 
2.1. Crystallisation and data collection 
Crystallisation was performed by the hanging drop vapour diffusion 
method using 24-well tissue culture plates. A 2 μΐ droplet of an 8 mg/ 
ml protein solution containing 10 mM phosphate buffer (pH 7.0), 
1 mM EDTA and 2 mM mercaptoethanol was mixed with equal 
volumes of a saturated solution of EA-GSH in 0.14% Triton X-100 
and reservoir solution. The EA-GSH was synthesised according to 
Ploemen and coworkers [5]. The drop was applied to a siliconised 
coverslip which was sealed to the top of the well with vacuum grease. 
Each well contained 1 ml of reservoir solution. The reservoir solution 
consisted of 25% (w/v) ammonium sulphate, 30-60 mM DTT, 100 mM 
MES buffer (pH range 6.2-6.4) and 5% (v/v) glycerol. The trials were 
carried out at a constant temperature of 22°C. The drops were al-
lowed to equilibrate for 1 day before they were streak-seeded with a 
cat's whisker from drops containing crystals grown under similar con-
ditions. Crystals appeared in the shape of plates after 1 week and grew 
to maximal dimensions of 0.1 mmXO.3 mmXO.3 mm. The complex 
crystallised in the space group C2 with cell dimensions я = 77.8 А, 
6 = 89.6 À, с = 68.7 A and β = 97.6°. 
The X-ray diffraction data were collected using a MARResearch 
area detector with CuKa X-rays generated by a Rigaku RU-200 ro-
tating anode X-ray generator. The data were collected at 100 К using 
an Oxford Cryosystems Cryostream Cooler. Prior to flash-freezing, 
the crystal was transferred to artificial mother liquor containing 
20% glycerol. The diffraction data were processed and analysed using 
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programs in the HKL [15] and CCP4 suites [16]. A data set off the one 
frozen crystal was collected to 2.3 A resolution with 84.3% complete-
ness (17 514 unique reflections), an //oj of 6.5 and a Asym of 13.0%. In 
the highest resolution bin, 2.35-2.30 A, the completeness was 90.7%, 
the 7/σι was 3.5 and the Äsym was 23.9%. 
2.2. Structure solution and refinement 
The starting model for refinement was the refined S-hexyl GSH 
complex model as observed in the C2 space group (Ä-factor = 20.0% 
and .Rfree = 24.5% for resolution limits 6.0-1.95 A; unpublished re-
sults). All water molecules and the S-hexyl GSH inhibitor were omit-
ted prior to use. Rigid body refinement in XPLOR version 3.1 [17] 
was used to compensate for any possible changes in crystal packing. 
As the asymmetric unit of the crystal contained two GST monomers, 
use was made of the non-crystallographic symmetry restraints on all 
non-hydrogen atoms throughout the course of refinement. The start-
ing model gave an Ä-factor of 37.4% (Rtee = 40.0%) which reduced to 
34.0% (Rfree = 35.8%) after rigid body refinement. The model was then 
subjected to two cycles of positional and isotropically restrained in-
dividual ΰ-factor refinement and inclusion of water and MES buffer 
molecules (Ä-factor = 23.8%, ^ « . = 30.1%). The 2Finhibitor— -fnative elec-
tron density map calculated from this model was further improved by 
10 cycles of twofold non-crystallographic averaging using MAMA 
[18], RAVE [18] and CCP4 [16] program suites. The averaged electron 
density maps allowed unambiguous placement of the inhibitor (Fig. 
2). The density for the chlorine atoms of the inhibitor was very clear. 
If the atoms at the chlorine positions were given scattering factors for 
carbon in the Fourier calculations, two strong peaks were positioned 
over both atoms confirming the identification of the chlorine atoms. 
The conjugation of GSH with EA can theoretically result in two 
possible diastereomers. After appropriate rotation of torsion angles 
so that each diastereomer would fit the electron density, the only 
significant difference between the two molecules is the positioning of 
the C9 and Cl 1 atoms of the ethyl group (see Fig. 3). The difference 
in positioning of these atoms is less than 0.6 A and is not distinguish-
able in the electron density maps. Because the electron density is 
broken over these atoms (Fig. 2), it is likely there is an approximately 
equal mixture of the two diastereomers. We have chosen only one 
diastereomer for simplicity. Bond lengths and angles for the inhibitor 
were derived from a model built and energy-minimised using pro-
grams in the INSIGHT II software suite (Molecular Simulations 
Inc., San Diego, CA, USA). The model was then subjected to a round 
of positional refinement (Ä-factor = 23.3%, Rflee = 29.2%). After two 
more rounds of refinement and rebuilding, the model yielded an 
Ä-factor of 21.9% (Rb<x = 28.1%). The temperature factors of the in-
hibitor were set to that of the surrounded side-chains and the inhib-
itor occupancies refined. The values obtained were 0.60 for the A 
monomer and 0.58 for the В monomer. After application of a bulk 
solvent correction the final Ä-factor was 21.4% (R{lee = 27.0%) for all 
data between 15.0 A and 2.3 A resolution. The root-mean-square 
(rms) deviations from ideal bond lengths and bond angles are 
0.009 A and 1.3°, respectively. The final model consists of 3262 
non-hydrogen protein atoms, 78 inhibitor atoms, 24 atoms corre-
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Fig. 1. Schematic representation of EA-GSH. The numbering 
scheme is taken from Lamotte and coworkers [22]. 
sponding to two MES buffer molecules and 174 water molecules. 
The fit of the inhibitor to the final electron density map is shown in 
Fig. 2. A stereochemical analysis of the refined structure with the 
program PROCHECK [19] gave values either similar to or better 
than expected for structures refined at similar resolutions. 
3. Results and discussion 
The human pi class G S T is a homodimer with 209 residues 
per monomer. The structure was originally determined from 
crystals of the enzyme complexed to the inhibitor, <S-hexyl 
G S H [20]. Each monomer was shown to consist of two do-
mains : the N-terminal domain (residues 1-76) and the C-ter-
minal domain (residues 83-209). The G S H binding site, or 
G site, was located in a cleft formed between the two domains 
and most of the residues contacting G S H are provided by 
residues from the N-terminal domain (Figs. 3 and 4). The 
binding site for the hydrophobic electrophile, or H site, was 
located immediately adjacent to the G site and formed part of 
the solvent-exposed cleft between the two domains. Residues 
in the H site are provided by both domains. 
The crystal structures of the human pi class GST complexed 
to EA and EA-GSH have recently been published [14]. The 
models were refined to 1.9 A resolution with crystallographic 
-R-factors of 21.0% and 20.6% respectively. In the EA com-
plex, the inhibitor was found in a similar position to that of 
the hexyl moiety of the previously determined 5-hexyl G S H 
complex crystal structure [20] (Figs. 3 and 5). The aromatic 
ring of the inhibitor was stacked between the aromatic side 
chains of Phe8 and Tyr108 and the inhibitor formed, in total, 
38 van der Waals interactions with the protein. In the 
EA-GSH complex, the G S H moiety was found to bind to 
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Fig. 2. Stereo diagram of the final 2i?ini1ibitor—-fcaic electron density map of the EA-GSH complex in the vicinity of the inhibitor binding site of 
human GST Pl-1. The map was calculated using all reflections between 40.0 A and 2.3 A and contoured at the 0.7σ level. 
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Fig. 3. Superposition of S'-hexyl GSH and EA-GSH structures in the vicinity of the active site. Filled grey bonds are for the S-hexyl GSH com-
plex structure [20], the unfilled bonds represent the EA-GSH complex structure, and the solid black bonds the alternative diastereomer of 
EA-GSH. The figure was generated with the program MOLSCRIPT [23]. 
Fig. 4. Schematic drawing of residues that interact with EA-GSH. This figure was produced using the program LIGPLOT [24]. 
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Fig. 5. Superposition of the inhibitor complex structures in the vicinity of the active site. Stippled bonds are for the previously published 
EA-GSH complex structure [14], hollow bonds for the published EA complex structure [14] and filled bonds are for the EA-GSH complex re-
ported here. The figure was generated with the program MOLSCRIPT [23]. 
the G site in identical fashion to that previously observed for 
the GSH moiety of the S-hexyl GSH complex. Surprisingly, 
the aromatic ring of EA was located in a very different posi-
tion to the position of the hexyl tail in the S-hexyl GSH 
complex and to the position of aromatic ring in the EA com-
plex (Fig. 5). Although still located in the H site, the aromatic 
ring of EA in the EA-GSH complex was shifted by 2.5 A and 
rotated by 120° compared to the aromatic ring in the EA 
complex. The structure of the human alpha class GST in 
complex with EA and its glutathione conjugate has recently 
been published [13]. As expected the aromatic ring of each 
complex binds in the H site and the GSH moiety binds in 
the G site. However, it is not straightforward to directly com-
pare the structures of the complexes from the alpha and pi 
class enzymes since these enzymes exhibit a low pairwise ami-
no acid sequence identity of only 32%. In particular, the 
H sites are very different due to even lower local sequence 
identity and to an additional C-terminal helix in the alpha 
class enzyme that forms part of the H site wall. 
The published structures of EA and EA-GSH bound to 
human pi class GST were based on preformed crystals of 
wild-type enzyme soaked in inhibitor solutions [14]. The 
EA-GSH complex presented here is based on crystals which 
formed by cocrystallisation of enzyme and inhibitor. We ob-
serve only one conformation of the inhibitor, unlike the ob-
served binding of EA-GSH to the alpha class enzyme [13]. (In 
the alpha class enzyme, two conformations were observed in 
which there was an approximately 140° rotation of the di-
chlorophenoxy group about the axis defined by the substitu-
ents off the C3 and C6 positions of the ring (Fig. 1).) The 
inhibitor sits in a very similar position to that of the S-hexyl 
GSH in the S-hexyl GSH complex structure (Fig. 3) [20]. The 
GSH moiety of the inhibitor makes essentially identical con-
tacts to residues in the G site of the enzyme as was observed 
with inhibitor S-hexyl GSH [20] and the published EA-GSH 
structure [14] (Figs. 3 and 4). In total, there are 147 van der 
Waals interactions ( < 4 A), 10 potential hydrogen bonding 
interactions and three salt bridges between protein and inhib-
itor (Fig. 4). Superposition of the new EA-GSH complex on 
the S-hexyl GSH complex structure (in the same space group) 
indicates no significant movement of side-chains in the active 
site (Fig. 3). The rms deviation in alpha-carbon positions is 
0.16 A, with no deviations greater than 0.5 A. 
The aromatic ring and chlorine atoms of the EA moiety of 
the EA-GSH complex reported here superimpose very closely 
to the aromatic ring and chlorine atoms of EA in the crystal 
structure of the E A complex [14] and there is no significant 
movement of side-chains within a 15 A sphere of the active 
site (Fig. 5). However, the carboxylate moiety now points out 
into the solvent and the butyryl group forms interactions with 
Tyr108 and He104 (Figs. 4 and 5). There is a big difference in 
the location of the aromatic rings between the previously 
published EA-GSH complex structure [14] and the one re-
ported here. The aromatic rings lie in the same plane but sit 
adjacent to one another with a shift of about 2.5 A, and the 
rings are rotated 120° to each other (Fig. 5). The aromatic 
ring of the previously published EA-GSH complex forms a 
parallel stacking interaction with the ring of Tyr108 [14] where-
as the aromatic ring of the EA-GSH complex reported here is 
positioned so it optimises packing interactions from the rings 
of both Tyr108 and Phe8. Surprisingly, there is essentially no 
difference in the number of contacts between inhibitor and 
protein in either complex (after ignoring water-mediated in-
teractions because the identification of water molecules are, in 
part, resolution-dependent). Both complexes have a total of 
120 protein-inhibitor contacts which include 10 hydrogen 
bonds and three salt bridges. The origin of the differences 
between the two complexes is puzzling but is likely related 
to the fact that in one case the complex was cocrystallised 
whereas in the other case the inhibitor was soaked into pre-
formed crystals. Both complexes were crystallised at room 
temperature in the same space group with the same cell di-
mensions and there are no crystal contacts in the vicinity of 
the active site in this crystal form. The X-ray diffraction data 
for both were collected off crystals frozen at 100 K. There was 
no evidence of the alternative binding mode seen in the elee-
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tron density maps of either complex, even when contoured at 
very low levels (0.3σ). 
In the previously published EA-GSH structure there is a 
water-mediated interaction between the EA ketone oxygen 
(08 in Fig. 1) and Tyr108 and this suggested a mechanism 
for the Michael addition of EA to GSH [14]. In the structure 
here the ketone oxygen is too far away (4.8 A) from Tyr108. 
However, the importance of the hydrogen bond for the cata-
lytic mechanism lies in the stereochemistry of the transition 
state rather than the product so no conclusions can be drawn 
from these observations. 
We have superimposed all the published pi class crystal 
structures which have GSH conjugates bound. These include 
the human enzyme in complex with 5-hexyl GSH [20] and the 
mouse enzyme in complex with S-hexyl GSH and S-(p-mtro-
benzyl) GSH [21]. The result demonstrates that EA [14] and 
the EA-GSH structure reported here bind in very similar po-
sitions to the other inhibitors. The aromatic rings of the EA 
inhibitors and the nitrobenzyl inhibitor almost superimpose 
with the rings lying in the same plane but slightly displaced 
from each other. Thus in both cases the aromatic rings are 
stacked between the side-chains of Phe8 and Tyr108. The EA 
inhibitors appear to fill the H site better because of the chlo-
rine substituents and in addition there are important van der 
Waals contacts between the butyryl moieties of the inhibitor 
and the protein. Just as there is no direct protein interaction 
with the carboxylate group of the EA-GSH, no interaction 
was found between the nitro group of the mouse GST inhib-
itor [21]. 
The observation that EA-GSH can bind to the pi class GST 
in different ways reflects the ability of the enzyme to react 
with a structurally diverse array of substrates. The possibility 
of multiple modes of ligand binding needs to be taken into 
account in any structure-based inhibitor design effort on the 
pi class GST. 
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